Report Detail
Global Pegturocoagulin alfa Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
- RnM4702036 |
- 01 June, 2026 |
- Global |
- 79 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Pegturocoagulin alfa market size was valued at US$ 1080 million in 2025 and is forecast to a readjusted size of US$ 3552 million by 2032 with a CAGR of 17.7% during review period.
Pegturocoagulin alfa is a long‑acting, pegylated recombinant coagulation factor VIII concentrate designed for the treatment of hemophilia A. It is produced through recombinant DNA technology and modified with polyethylene glycol (PEG) to extend its circulating half‑life, reducing the frequency of intravenous administration. By replenishing the deficient or dysfunctional factor VIII, it restores the blood clotting cascade, effectively preventing and controlling bleeding episodes, maintaining hemostasis, and supporting routine prophylaxis in children and adults with congenital factor VIII deficiency.In 2025, global Pegturocoagulin alfa (Esperoct) production reached approximately 3.2–3.5 million vials.
Pegturocoagulin alfa operates within the high-growth, innovation-driven global hemophilia A therapeutics market, where the shift from standard half-life to extended half-life (EHL) recombinant factor VIII products defines the core competitive dynamic. As a leading PEGylated EHL FVIII therapy, it benefits from strong clinical demand driven by its significantly prolonged half-life, which reduces infusion frequency, improves treatment adherence, and enhances long-term bleeding control and quality of life—key unmet needs for patients requiring lifelong prophylaxis. Its market position is reinforced by global regulatory approvals across major regions and recent access expansion via reimbursement in key markets, including China, which broadens its commercial reach and patient accessibility. The product competes in a landscape shaped by other EHL FVIII agents, emerging non-factor therapies, and advancing gene therapy pipelines, yet maintains a robust presence due to its well-established efficacy, safety profile, and real-world evidence base. Growth is further supported by the global trend toward proactive, routine prophylaxis over on-demand treatment, rising hemophilia diagnosis rates, and ongoing efforts to improve care access in underserved regions. While facing pricing pressures, manufacturing constraints, and intensifying competition, pegturocoagulin alfa remains a cornerstone of modern hemophilia A management, with its market trajectory tied to sustained innovation, expanding reimbursement, and evolving patient-centric care standards in the rare bleeding disorders space
This report is a detailed and comprehensive analysis for global Pegturocoagulin alfa market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Pegturocoagulin alfa market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Pegturocoagulin alfa market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Pegturocoagulin alfa market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Pegturocoagulin alfa market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Pegturocoagulin alfa
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Pegturocoagulin alfa market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk A/S, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Pegturocoagulin alfa market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
500 IU / vial
1000 IU / vial
Market segment by Dosage Form
Powder for Solution for Injection
Injectable Preparation
Market segment by Route of Administration
Intravenous Infusion
Intravenous Injection
Market segment by Sales Channels
Hospitals
Retail
Online
Market segment by Application
Hemophilia A
Congenital Factor VIII Deficiency
Others
Major players covered
Novo Nordisk A/S
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Pegturocoagulin alfa product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Pegturocoagulin alfa, with price, sales quantity, revenue, and global market share of Pegturocoagulin alfa from 2021 to 2026.
Chapter 3, the Pegturocoagulin alfa competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Pegturocoagulin alfa breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Pegturocoagulin alfa market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Pegturocoagulin alfa.
Chapter 14 and 15, to describe Pegturocoagulin alfa sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Pegturocoagulin alfa Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 500 IU / vial
- 1.3.3 1000 IU / vial
- 1.4 Market Analysis by Dosage Form
- 1.4.1 Overview: Global Pegturocoagulin alfa Consumption Value by Dosage Form: 2021 Versus 2025 Versus 2032
- 1.4.2 Powder for Solution for Injection
- 1.4.3 Injectable Preparation
- 1.5 Market Analysis by Route of Administration
- 1.5.1 Overview: Global Pegturocoagulin alfa Consumption Value by Route of Administration: 2021 Versus 2025 Versus 2032
- 1.5.2 Intravenous Infusion
- 1.5.3 Intravenous Injection
- 1.6 Market Analysis by Sales Channels
- 1.6.1 Overview: Global Pegturocoagulin alfa Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
- 1.6.2 Hospitals
- 1.6.3 Retail
- 1.6.4 Online
- 1.7 Market Analysis by Application
- 1.7.1 Overview: Global Pegturocoagulin alfa Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.7.2 Hemophilia A
- 1.7.3 Congenital Factor VIII Deficiency
- 1.7.4 Others
- 1.8 Global Pegturocoagulin alfa Market Size & Forecast
- 1.8.1 Global Pegturocoagulin alfa Consumption Value (2021 & 2025 & 2032)
- 1.8.2 Global Pegturocoagulin alfa Sales Quantity (2021-2032)
- 1.8.3 Global Pegturocoagulin alfa Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 Novo Nordisk A/S
- 2.1.1 Novo Nordisk A/S Details
- 2.1.2 Novo Nordisk A/S Major Business
- 2.1.3 Novo Nordisk A/S Pegturocoagulin alfa Product and Services
- 2.1.4 Novo Nordisk A/S Pegturocoagulin alfa Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Novo Nordisk A/S Recent Developments/Updates
3 Competitive Environment: Pegturocoagulin alfa by Manufacturer
- 3.1 Global Pegturocoagulin alfa Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Pegturocoagulin alfa Revenue by Manufacturer (2021-2026)
- 3.3 Global Pegturocoagulin alfa Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Pegturocoagulin alfa by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Pegturocoagulin alfa Manufacturer Market Share in 2025
- 3.4.3 Top 6 Pegturocoagulin alfa Manufacturer Market Share in 2025
- 3.5 Pegturocoagulin alfa Market: Overall Company Footprint Analysis
- 3.5.1 Pegturocoagulin alfa Market: Region Footprint
- 3.5.2 Pegturocoagulin alfa Market: Company Product Type Footprint
- 3.5.3 Pegturocoagulin alfa Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Pegturocoagulin alfa Market Size by Region
- 4.1.1 Global Pegturocoagulin alfa Sales Quantity by Region (2021-2032)
- 4.1.2 Global Pegturocoagulin alfa Consumption Value by Region (2021-2032)
- 4.1.3 Global Pegturocoagulin alfa Average Price by Region (2021-2032)
- 4.2 North America Pegturocoagulin alfa Consumption Value (2021-2032)
- 4.3 Europe Pegturocoagulin alfa Consumption Value (2021-2032)
- 4.4 Asia-Pacific Pegturocoagulin alfa Consumption Value (2021-2032)
- 4.5 South America Pegturocoagulin alfa Consumption Value (2021-2032)
- 4.6 Middle East & Africa Pegturocoagulin alfa Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Pegturocoagulin alfa Sales Quantity by Type (2021-2032)
- 5.2 Global Pegturocoagulin alfa Consumption Value by Type (2021-2032)
- 5.3 Global Pegturocoagulin alfa Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Pegturocoagulin alfa Sales Quantity by Application (2021-2032)
- 6.2 Global Pegturocoagulin alfa Consumption Value by Application (2021-2032)
- 6.3 Global Pegturocoagulin alfa Average Price by Application (2021-2032)
7 North America
- 7.1 North America Pegturocoagulin alfa Sales Quantity by Type (2021-2032)
- 7.2 North America Pegturocoagulin alfa Sales Quantity by Application (2021-2032)
- 7.3 North America Pegturocoagulin alfa Market Size by Country
- 7.3.1 North America Pegturocoagulin alfa Sales Quantity by Country (2021-2032)
- 7.3.2 North America Pegturocoagulin alfa Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Pegturocoagulin alfa Sales Quantity by Type (2021-2032)
- 8.2 Europe Pegturocoagulin alfa Sales Quantity by Application (2021-2032)
- 8.3 Europe Pegturocoagulin alfa Market Size by Country
- 8.3.1 Europe Pegturocoagulin alfa Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Pegturocoagulin alfa Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Pegturocoagulin alfa Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Pegturocoagulin alfa Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Pegturocoagulin alfa Market Size by Region
- 9.3.1 Asia-Pacific Pegturocoagulin alfa Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Pegturocoagulin alfa Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Pegturocoagulin alfa Sales Quantity by Type (2021-2032)
- 10.2 South America Pegturocoagulin alfa Sales Quantity by Application (2021-2032)
- 10.3 South America Pegturocoagulin alfa Market Size by Country
- 10.3.1 South America Pegturocoagulin alfa Sales Quantity by Country (2021-2032)
- 10.3.2 South America Pegturocoagulin alfa Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Pegturocoagulin alfa Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Pegturocoagulin alfa Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Pegturocoagulin alfa Market Size by Country
- 11.3.1 Middle East & Africa Pegturocoagulin alfa Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Pegturocoagulin alfa Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Pegturocoagulin alfa Market Drivers
- 12.2 Pegturocoagulin alfa Market Restraints
- 12.3 Pegturocoagulin alfa Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Pegturocoagulin alfa and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Pegturocoagulin alfa
- 13.3 Pegturocoagulin alfa Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Pegturocoagulin alfa Typical Distributors
- 14.3 Pegturocoagulin alfa Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Pegturocoagulin alfa. Industry analysis & Market Report on Pegturocoagulin alfa is a syndicated market report, published as Global Pegturocoagulin alfa Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Pegturocoagulin alfa market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
